Cardiac Resynchronization Therapy in Mild Heart Failure
Cardiac resynchronization therapy (CRT) has traditionally been associated with patients who have advanced systolic heart failure, yet its role in mild heart failure is equally important. In carefully selected patients, early biventricular pacing can reduce ventricular dyssynchrony, promote reverse remodeling, lower heart-failure hospitalization, and provide a long-term survival advantage.
The strongest evidence comes from patients with left bundle branch block (LBBB), a reduced left ventricular ejection fraction (LVEF), and a prolonged QRS complex who remain in New York Heart Association (NYHA) functional class I or II. These patients may feel relatively well while still carrying a substantial risk of progressive ventricular dysfunction and sudden cardiac death.
The clinical question is therefore more precise than whether CRT benefits mild heart failure generally. It is whether the expected benefit of resynchronization outweighs procedural risks in a patient whose symptoms are limited, particularly when guideline-directed medical therapy is already being used. Current research and educational material from the Journal of Arrhythmia provide valuable context for this evolving area of electrophysiology.
Why Early Ventricular Resynchronization Matters
Heart failure with reduced ejection fraction is often accompanied by electrical and mechanical dyssynchrony. A delayed left ventricular activation pattern, especially LBBB, can cause the septum and lateral wall to contract out of sequence. This reduces pumping efficiency, increases wall stress, and may accelerate adverse remodeling even before symptoms become severe.
CRT coordinates ventricular activation through leads positioned in the right ventricle and a coronary venous branch over the left ventricle. In suitable patients, this can improve stroke volume and mitral valve function while reducing end-systolic volume. Reverse remodeling may continue over months or years, which helps explain why the clinical value of CRT can extend well beyond the initial improvement in exercise tolerance.
Mild symptoms should not be confused with mild disease. A patient in NYHA class II may have a markedly reduced LVEF, extensive myocardial scar, or a high risk of hospitalization. CRT is therefore a risk-modifying treatment rather than a therapy reserved solely for breathless or frequently hospitalized patients.
What Long-Term Trials Have Shown
The major trials in this field examined patients with relatively mild symptoms and reduced ventricular function. MADIT-CRT demonstrated that CRT with defibrillation capability reduced heart-failure events compared with an implantable cardioverter-defibrillator (ICD) alone, with the clearest benefit in participants with LBBB. Extended follow-up suggested that patients with LBBB also experienced lower long-term mortality, whereas the survival effect was much less consistent in those with non-LBBB conduction patterns.
REVERSE evaluated patients with NYHA class I or II symptoms and found that CRT was associated with favorable structural remodeling and fewer heart-failure events over follow-up. Its mortality findings were less definitive because the study was not designed primarily to detect a survival difference. RAFT, which included patients with mild-to-moderate symptoms, also showed reductions in heart-failure hospitalization and mortality with CRT-D compared with ICD therapy alone, although procedural complications were more frequent.
Together, these studies support an important interpretation: early CRT can alter the disease trajectory, but the benefit is concentrated in a recognizable phenotype. A prolonged QRS by itself is insufficient. LBBB morphology, a low LVEF, appropriate chamber size, and a reasonable expectation of high biventricular pacing are central to the likelihood of benefit.
Patient Features That Shape Benefit
Contemporary guideline pathways commonly consider CRT for patients with an LVEF of 35% or less, sinus rhythm, LBBB, and a QRS duration of at least 150 milliseconds, particularly when symptoms remain in NYHA class II despite optimized medical therapy. Recommendations may be weaker when the QRS is 120–149 milliseconds, when the conduction pattern is non-LBBB, or when symptoms are minimal without other high-risk features.
The cause of cardiomyopathy also matters. Patients with nonischemic cardiomyopathy often show substantial reverse remodeling, while patients with ischemic cardiomyopathy may have scar that limits electrical capture and mechanical response. Scar burden, lead position, atrial rhythm, renal function, frailty, and competing noncardiac illness should all inform the decision.
A patient with atrial fibrillation can benefit from CRT, but effective delivery of near-continuous biventricular pacing is essential. In some cases, atrioventricular node ablation is considered to prevent competing intrinsic conduction. Similarly, patients who require a high percentage of right ventricular pacing may be candidates for an upgrade to CRT when pacing-induced cardiomyopathy develops.
| Clinical feature | Expected relevance to CRT | Practical interpretation |
|---|---|---|
| LBBB morphology | Strongest association with response | Particularly persuasive when QRS is at least 150 ms |
| QRS duration 150 ms or longer | Higher likelihood of electrical dyssynchrony | Usually supports a stronger recommendation |
| QRS 120–149 ms | More variable response | Consider the full clinical phenotype rather than duration alone |
| LVEF 35% or less | Core eligibility feature in many pathways | Confirm persistent dysfunction after medical therapy |
| NYHA class II symptoms | Evidence supports prevention of progression | Mild symptoms do not eliminate meaningful risk |
| Non-LBBB pattern | Lower and less predictable response | Benefit should be assessed cautiously |
| High expected pacing burden | Opportunity to prevent pacing-related dysfunction | CRT or conduction-system pacing may be considered |
Measuring Survival Beyond Hospitalization
The survival signal associated with CRT is closely linked to fewer worsening-heart-failure events. Patients who avoid repeated congestion, escalating diuretics, and hospitalization may preserve renal function, exercise capacity, and independence for longer. CRT can also reduce ventricular volumes and improve functional mitral regurgitation, mechanisms that may reduce later decompensation.
However, survival should not be presented as guaranteed or uniform. Sudden death, progressive pump failure, ischemic disease, infection, malignancy, and other comorbid conditions may dominate the long-term outcome. The defibrillator component of CRT-D can reduce the risk of death from malignant ventricular arrhythmias, but it also introduces risks such as inappropriate shocks, lead failure, generator replacement, and infection.
CRT-P may be appropriate for selected patients when the primary goal is hemodynamic improvement and the expected value of defibrillation is limited. CRT-D may be favored when the patient meets established criteria for primary-prevention ICD therapy and has a meaningful life expectancy with acceptable functional status. This distinction requires individualized discussion rather than automatic selection of one device type.
Implantation, Response, And Device Strategy
Implantation is generally safe, but it is more complex than conventional pacemaker or ICD placement. Potential complications include pneumothorax, lead dislodgement, coronary sinus injury, venous obstruction, infection, and failure to achieve satisfactory left ventricular lead thresholds. The chance of complications must be balanced against the expected reduction in heart-failure events.
A proportion of patients show limited symptomatic or echocardiographic improvement. Reasons include extensive myocardial scar, suboptimal left ventricular lead location, phrenic nerve stimulation, atrial fibrillation, frequent premature ventricular contractions, or inadequate pacing percentage. Device interrogation and systematic follow-up can identify these problems. Programming adjustments, arrhythmia treatment, lead revision, or alternative pacing approaches may improve delivery.
Device selection also sits within a broader sudden-death prevention strategy. For example, the Journal of Arrhythmia discussion of subcutaneous ICD selection illustrates how anatomy, pacing needs, and arrhythmic risk influence device choice. A subcutaneous ICD does not provide CRT, so it is unsuitable when ventricular resynchronization is needed, but the comparison reinforces the importance of matching device capabilities to the patient’s electrophysiologic problem.
Applying Evidence At The Point Of Care
The most reliable approach begins with confirmation that heart-failure therapy is optimized. Angiotensin receptor-neprilysin inhibitors or appropriate renin-angiotensin system therapy, beta blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 inhibitors may improve outcomes and alter LVEF. Reassessment after treatment helps determine whether electrical dyssynchrony and ventricular dysfunction persist.
Imaging should confirm LVEF and evaluate valve disease, chamber dimensions, right ventricular function, and possible myocardial scar. A 12-lead ECG is indispensable because QRS morphology often predicts response more accurately than duration alone. The clinician should also estimate pacing dependence, rhythm stability, procedural risk, and the patient’s goals regarding longevity, hospitalization, shocks, and quality of life.
Patients with mild symptoms may need especially clear counseling. The expected benefit is often preventive and may not be felt immediately, while device implantation creates lifelong follow-up obligations. Shared decision-making should explain the possibility of reverse remodeling and improved event-free survival alongside the risks of complications, generator procedures, lead problems, and inappropriate therapy.
Practical Priorities For Clinical Teams
- Confirm persistent LVEF reduction after evidence-based medical therapy and address reversible causes of cardiomyopathy.
- Give greatest weight to LBBB morphology, QRS duration, sinus rhythm, and the likelihood of sustained biventricular pacing.
- Distinguish the goals of CRT-P and CRT-D, including symptom prevention, heart-failure risk reduction, and sudden-death protection.
- Assess scar burden, comorbidity, frailty, life expectancy, and the patient’s preferences before implantation.
- Arrange structured follow-up to verify pacing percentage, lead performance, rhythm control, ventricular remodeling, and clinical response.
The evidence supports offering CRT earlier to selected patients rather than waiting for severe functional limitation. Its long-term survival advantage is most credible when mild heart failure occurs alongside marked LBBB-related dyssynchrony and substantial systolic dysfunction. Careful selection remains more important than treating symptom class in isolation.
Clinicians and trainees can use the Journal of Arrhythmia’s open-access research, reviews, guidelines, and device-focused education to refine patient selection and follow-up strategies. Applying that evidence at the bedside helps ensure that early CRT is used where its potential to preserve ventricular function and extend meaningful survival is greatest.